肺动脉高压的治疗研究进展
Research Progress in the Treatment of Pulmonary Hypertension
DOI: 10.12677/acm.2026.1631096, PDF,    科研立项经费支持
作者: 杨 菌, 刘彩娥, 贾成真, 吴金婷：湖北文理学院基础医学院，湖北 襄阳；范晓航*：湖北文理学院基础医学院，湖北 襄阳；湖北文理学院附属医院襄阳市中心医院心血管疾病研究所，湖北 襄阳
关键词: 肺动脉高压；药物治疗；基因治疗；干细胞治疗；介入与外科手术；Pulmonary Hypertension； Drug Therapy； Gene Therapy； Stem Cell Therapy； Interventional and Surgical Procedures
摘要: 肺动脉高压(pulmonary hypertension, PH)是一种以肺血管结构或功能改变，引起肺血管阻力和肺动脉压力进行性升高、最终导致右心衰竭乃至死亡为特征的恶性心血管疾病。目前，肺动脉高压的病理生理学机制并不完全明确，且患病率和死亡率较高，虽然靶向药物的应用显著改善了患者生存率，但PH仍是一种高致死性疾病。因而需持续对诊疗理念与策略进行改进和创新来支持患者，改善患者的生存质量。目前，PH的治疗策略已从单一支持治疗发展为以靶向药物联合治疗为核心的综合管理。传统的药物治疗结合基因治疗、干细胞治疗、介入与外科手术等手段，对治疗方案进行优化，提高了治疗的可行性，有效改善患者预后。本文结合以往文献对PH的治疗进展进行综述。
Abstract: Pulmonary hypertension (PH) is a malignant cardiovascular disease characterized by alterations in pulmonary vascular structure or function, leading to progressive increases in pulmonary vascular resistance and pulmonary arterial pressure, which ultimately result in right heart failure and death. Currently, the pathophysiological mechanisms of PH are not fully elucidated, and both prevalence and mortality remain high; although the application of targeted therapies has significantly improved survival rates, PH remains a highly fatal condition. Therefore, ongoing refinement and innovation in diagnostic and therapeutic concepts and strategies are essential to support patients and enhance their quality of life. Now, the treatment strategy for PH has evolved from sole supportive care to comprehensive management centered on combination targeted therapy. Optimization of treatment regimens—incorporating conventional pharmacological treatments with approaches such as gene therapy, stem cell therapy, and interventional or surgical procedures—enhances feasibility and effectively improves prognosis. This study reviews the advances in PH treatment based on previous literature.
文章引用：杨菌, 刘彩娥, 贾成真, 吴金婷, 范晓航. 肺动脉高压的治疗研究进展[J]. 临床医学进展, 2026, 16(3): 2930-2939. https://doi.org/10.12677/acm.2026.1631096

参考文献

[1] Shah, A.J., Vorla, M. and Kalra, D.K. (2022) Molecular Pathways in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 23, Article 10001. [Google Scholar] [CrossRef] [PubMed]
[2] Mocumbi, A., Humbert, M., Saxena, A., Jing, Z., Sliwa, K., Thienemann, F., et al. (2024) Pulmonary Hypertension. Nature Reviews Disease Primers, 10, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[3] Maron, B.A. and Galiè, N. (2016) Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. JAMA Cardiology, 1, 1056-1065. [Google Scholar] [CrossRef] [PubMed]
[4] Wu, Z., Zhu, L., Nie, X., Wei, L. and Qi, Y. (2023) USP15 Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension in a YAP1/TAZ-Dependent Manner. Experimental & Molecular Medicine, 55, 183-195. [Google Scholar] [CrossRef] [PubMed]
[5] Adu-Amankwaah, J., Shi, Y., Song, H., Ma, Y., Liu, J., Wang, H., et al. (2025) Signaling Pathways and Targeted Therapy for Pulmonary Hypertension. Signal Transduction and Targeted Therapy, 10, Article No. 207. [Google Scholar] [CrossRef] [PubMed]
[6] Chin, K.M., Gaine, S.P., Gerges, C., Jing, Z., Mathai, S.C., Tamura, Y., et al. (2024) Treatment Algorithm for Pulmonary Arterial Hypertension. European Respiratory Journal, 64, Article ID: 2401325. [Google Scholar] [CrossRef] [PubMed]
[7] Sauvageau, S., Thorin, E., Villeneuve, L. and Dupuis, J. (2009) Change in Pharmacological Effect of Endothelin Receptor Antagonists in Rats with Pulmonary Hypertension: Role of ETB-Receptor Expression Levels. Pulmonary Pharmacology & Therapeutics, 22, 311-317. [Google Scholar] [CrossRef] [PubMed]
[8] Kawanabe, Y. and Nauli, S.M. (2010) Endothelin. Cellular and Molecular Life Sciences, 68, 195-203. [Google Scholar] [CrossRef] [PubMed]
[9] de Nucci, G., Thomas, R., D’Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., et al. (1988) Pressor Effects of Circulating Endothelin Are Limited by Its Removal in the Pulmonary Circulation and by the Release of Prostacyclin and Endothelium-Derived Relaxing Factor. Proceedings of the National Academy of Sciences of the United States of America, 85, 9797-9800. [Google Scholar] [CrossRef] [PubMed]
[10] D’Orléans‐Juste, P., Claing, A., Télémaque, S., Maurice, M., Yano, M. and Gratton, J. (1994) Block of Endothelin‐1‐Induced Release of Thromboxane A2 from the Guinea Pig Lung and Nitric Oxide from the Rabbit Kidney by a Selective ETB Receptor Antagonist, Bq‐788. British Journal of Pharmacology, 113, 1257-1262. [Google Scholar] [CrossRef] [PubMed]
[11] Saleh, J.A. (2008) Role of Iloprost and Bosentan in Pulmonary Arterial Hypertension. Nigerian Journal of Medicine, 17, 13-19. [Google Scholar] [CrossRef] [PubMed]
[12] Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., et al. (2008) Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation, 117, 3010-3019. [Google Scholar] [CrossRef] [PubMed]
[13] Pulido, T., Adzerikho, I., Channick, R.N., Delcroix, M., Galiè, N., Ghofrani, H., et al. (2013) Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 369, 809-818. [Google Scholar] [CrossRef] [PubMed]
[14] Denninger, J.W. and Marletta, M.A. (1999) Guanylate Cyclase and the ⋅NO/cGMP Signaling Pathway. Biochimica et Biophysica Acta (BBA)—Bioenergetics, 1411, 334-350. [Google Scholar] [CrossRef] [PubMed]
[15] Klinger, J.R. (2007) The Nitric Oxide/cGMP Signaling Pathway in Pulmonary Hypertension. Clinics in Chest Medicine, 28, 143-167. [Google Scholar] [CrossRef] [PubMed]
[16] Bogdan, M., Humbert, M., Francoual, J., Claise, C., Duroux, P., Simonneau, G., et al. (1998) Urinary cGMP Concentrations in Severe Primary Pulmonary Hypertension. Thorax, 53, 1059-1062. [Google Scholar] [CrossRef] [PubMed]
[17] Stasch, J., Pacher, P. and Evgenov, O.V. (2011) Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation, 123, 2263-2273. [Google Scholar] [CrossRef] [PubMed]
[18] Mubarak, K.K. (2010) A Review of Prostaglandin Analogs in the Management of Patients with Pulmonary Arterial Hypertension. Respiratory Medicine, 104, 9-21. [Google Scholar] [CrossRef] [PubMed]
[19] Vanderpool, R.R., Desai, A.A., Knapp, S.M., Simon, M.A., Abidov, A., Yuan, J.X., et al. (2017) How Prostacyclin Therapy Improves Right Ventricular Function in Pulmonary Arterial Hypertension. European Respiratory Journal, 50, Article ID: 1700764. [Google Scholar] [CrossRef] [PubMed]
[20] Sitbon, O., Channick, R., Chin, K.M., Frey, A., Gaine, S., Galiè, N., et al. (2015) Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 373, 2522-2533. [Google Scholar] [CrossRef] [PubMed]
[21] Lane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Phillips, J.A., Loyd, J.E., et al. (2000) Heterozygous Germline Mutations in BMPR2, Encoding a TGF-β Receptor, Cause Familial Primary Pulmonary Hypertension. Nature Genetics, 26, 81-84. [Google Scholar] [CrossRef] [PubMed]
[22] Evans, J.D.W., Girerd, B., Montani, D., Wang, X., Galiè, N., Austin, E.D., et al. (2016) BMPR2 Mutations and Survival in Pulmonary Arterial Hypertension: An Individual Participant Data Meta-Analysis. The Lancet Respiratory Medicine, 4, 129-137. [Google Scholar] [CrossRef] [PubMed]
[23] Tojais, N.F., Cao, A., Lai, Y., Wang, L., Chen, P., Alcazar, M.A.A., et al. (2017) Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-Β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 37, 1559-1569. [Google Scholar] [CrossRef] [PubMed]
[24] Kumar, R., Nolan, K., Kassa, B., Chanana, N., Palmo, T., Sharma, K., et al. (2025) Monocytes and Interstitial Macrophages Contribute to Hypoxic Pulmonary Hypertension. Journal of Clinical Investigation, 135, e176865. [Google Scholar] [CrossRef] [PubMed]
[25] Austin, E.D. and Loyd, J.E. (2014) The Genetics of Pulmonary Arterial Hypertension. Circulation Research, 115, 189-202. [Google Scholar] [CrossRef] [PubMed]
[26] Rabinovitch, M., Guignabert, C., Humbert, M. and Nicolls, M.R. (2014) Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 115, 165-175. [Google Scholar] [CrossRef] [PubMed]
[27] Johnson, S., Sommer, N., Cox-Flaherty, K., Weissmann, N., Ventetuolo, C.E. and Maron, B.A. (2023) Pulmonary Hypertension: A Contemporary Review. American Journal of Respiratory and Critical Care Medicine, 208, 528-548. [Google Scholar] [CrossRef] [PubMed]
[28] Humbert, M., McLaughlin, V.V., Badesch, D.B., Ghofrani, H.A., Gibbs, J.S.R., Gomberg-Maitland, M., et al. (2025) Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. New England Journal of Medicine, 392, 1987-2000. [Google Scholar] [CrossRef] [PubMed]
[29] Anand, S.C., Furqan, M., Tonelli, A.R., Brady, D., Levine, A., Rosenzweig, E.B., et al. (2025) Sotatercept: A New Era in Pulmonary Arterial Hypertension. Cardiology in Review. [Google Scholar] [CrossRef] [PubMed]
[30] Galiè, N., Humbert, M., Vachiery, J., Gibbs, S., Lang, I., Torbicki, A., et al. (2015) 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Heart Journal, 37, 67-119. [Google Scholar] [CrossRef] [PubMed]
[31] Galiè, N., Humbert, M., Vachiery, J., Gibbs, S., Lang, I., Torbicki, A., et al. (2015) 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Respiratory Journal, 46, 903-975. [Google Scholar] [CrossRef] [PubMed]
[32] Coghlan, J.G., Channick, R., Chin, K., Di Scala, L., Galiè, N., Ghofrani, H., et al. (2018) Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 18, 37-47. [Google Scholar] [CrossRef] [PubMed]
[33] Galiè, N., Barberà, J.A., Frost, A.E., Ghofrani, H., Hoeper, M.M., McLaughlin, V.V., et al. (2015) Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 373, 834-844. [Google Scholar] [CrossRef] [PubMed]
[34] Xue, Z., Li, Y., Zhou, M., Liu, Z., Fan, G., Wang, X., et al. (2021) Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 12, Article 720873. [Google Scholar] [CrossRef] [PubMed]
[35] Lu, Y., Wu, J., Sun, Y., Xin, L., Jiang, Z., Lin, H., Zhao, M. and Cui, X. (2020) Qiliqiangxin Prevents Right Ventricular Remodeling by Inhibiting Apoptosis and Improving Metabolism Reprogramming with Pulmonary Arterial Hypertension. American Journal of Translational Research, 12, 5655-5669.
[36] Yu, P.B., Deng, D.Y., Beppu, H., Hong, C.C., Lai, C., Hoyng, S.A., et al. (2008) Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for Bmp-Mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells. Journal of Biological Chemistry, 283, 3877-3888. [Google Scholar] [CrossRef] [PubMed]
[37] Hadri, L., Kratlian, R.G., Benard, L., Maron, B.A., Dorfmüller, P., Ladage, D., et al. (2013) Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 128, 512-523. [Google Scholar] [CrossRef] [PubMed]
[38] Bisserier, M., Mathiyalagan, P., Zhang, S., Elmastour, F., Dorfmüller, P., Humbert, M., et al. (2021) Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 144, 52-73. [Google Scholar] [CrossRef] [PubMed]
[39] Bisserier, M., Katz, M.G., Bueno-Beti, C., Brojakowska, A., Zhang, S., Gubara, S., et al. (2021) Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 22, Article 9105. [Google Scholar] [CrossRef] [PubMed]
[40] Ding, Y., Tu, P., Chen, Y., Huang, Y., Pan, X. and Chen, W. (2021) CYP2J2 and EETs Protect against Pulmonary Arterial Hypertension with Lung Ischemia-Reperfusion Injury in Vivo and in Vitro. Respiratory Research, 22, Article No. 291. [Google Scholar] [CrossRef] [PubMed]
[41] Brimble, M.A., Winston, S.M. and Davidoff, A.M. (2023) Stowaways in the Cargo: Contaminating Nucleic Acids in Raav Preparations for Gene Therapy. Molecular Therapy, 31, 2826-2838. [Google Scholar] [CrossRef] [PubMed]
[42] Ding, X., Liang, H., Yuan, B., Li, L., Wang, T., Kan, Q., et al. (2019) Efficacy of Stem Cell Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Preclinical Studies. Stem Cell Research & Therapy, 10, Article No. 55. [Google Scholar] [CrossRef] [PubMed]
[43] Wang, C., Cherng, W., Yang, N., Kuo, L., Hsu, C., Yeh, H., et al. (2008) Late-Outgrowth Endothelial Cells Attenuate Intimal Hyperplasia Contributed by Mesenchymal Stem Cells after Vascular Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 54-60. [Google Scholar] [CrossRef] [PubMed]
[44] Aslam, M., Baveja, R., Liang, O.D., Fernandez-Gonzalez, A., Lee, C., Mitsialis, S.A., et al. (2009) Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 180, 1122-1130. [Google Scholar] [CrossRef] [PubMed]
[45] Mansouri, N., Willis, G.R., Fernandez-Gonzalez, A., Reis, M., Nassiri, S., Mitsialis, S.A., et al. (2019) Mesenchymal Stromal Cell Exosomes Prevent and Revert Experimental Pulmonary Fibrosis through Modulation of Monocyte Phenotypes. JCI Insight, 4, e128060. [Google Scholar] [CrossRef] [PubMed]
[46] de Mendonça, L., Felix, N.S., Blanco, N.G., Da Silva, J.S., Ferreira, T.P., Abreu, S.C., et al. (2017) Mesenchymal Stromal Cell Therapy Reduces Lung Inflammation and Vascular Remodeling and Improves Hemodynamics in Experimental Pulmonary Arterial Hypertension. Stem Cell Research & Therapy, 8, Article No. 220. [Google Scholar] [CrossRef] [PubMed]
[47] Shao, F., Liu, R., Tan, X., Zhang, Q., Ye, L., Yan, B., et al. (2022) MSC Transplantation Attenuates Inflammation, Prevents Endothelial Damage and Enhances the Angiogenic Potency of Endogenous MSCs in a Model of Pulmonary Arterial Hypertension. Journal of Inflammation Research, 15, 2087-2101. [Google Scholar] [CrossRef] [PubMed]
[48] Aliotta, J.M., Pereira, M., Wen, S., Dooner, M.S., Del Tatto, M., Papa, E., et al. (2016) Exosomes Induce and Reverse Monocrotaline-Induced Pulmonary Hypertension in Mice. Cardiovascular Research, 110, 319-330. [Google Scholar] [CrossRef] [PubMed]
[49] Khan, M.S., Memon, M.M., Amin, E., Yamani, N., Khan, S.U., Figueredo, V.M., et al. (2019) Use of Balloon Atrial Septostomy in Patients with Advanced Pulmonary Arterial Hypertension. Chest, 156, 53-63. [Google Scholar] [CrossRef] [PubMed]
[50] Kurzyna, M., Dąbrowski, M., Bielecki, D., Fijalkowska, A., Pruszczyk, P., Opolski, G., et al. (2007) Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients with Pulmonary Hypertension. Chest, 131, 977-983. [Google Scholar] [CrossRef] [PubMed]
[51] Yan, C., Niu, G., Niu, H., Li, L., Wan, L. and Li, H. (2018) Stable Interatrial Communication Combining Balloon Atrial Septostomy and Radiofrequency Catheter Ablation. Journal of the American College of Cardiology, 72, 1873-1875. [Google Scholar] [CrossRef] [PubMed]
[52] Yan, C., Wan, L., Li, H., Wang, C., Guo, T., Niu, H., et al. (2022) First In-Human Modified Atrial Septostomy Combining Radiofrequency Ablation and Balloon Dilation. Heart, 108, 1690-1698. [Google Scholar] [CrossRef] [PubMed]
[53] López-Meseguer, M., Quezada, C.A., Ramon, M.A., Lázaro, M., Dos, L., Lara, A., et al. (2017) Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension. PLOS ONE, 12, e0187811. [Google Scholar] [CrossRef] [PubMed]
[54] Weill, D., Benden, C., Corris, P.A., Dark, J.H., Davis, R.D., Keshavjee, S., et al. (2015) A Consensus Document for the Selection of Lung Transplant Candidates: 2014—An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. The Journal of Heart and Lung Transplantation, 34, 1-15. [Google Scholar] [CrossRef] [PubMed]
[55] Corris, P. and Degano, B. (2014) Severe Pulmonary Arterial Hypertension: Treatment Options and the Bridge to Transplantation. European Respiratory Review, 23, 488-497. [Google Scholar] [CrossRef] [PubMed]
[56] Tudorache, I., Sommer, W., Kühn, C., Wiesner, O., Hadem, J., Fühner, T., et al. (2015) Lung Transplantation for Severe Pulmonary Hypertension—Awake Extracorporeal Membrane Oxygenation for Postoperative Left Ventricular Remodelling. Transplantation, 99, 451-458. [Google Scholar] [CrossRef] [PubMed]
[57] Moser, B., Jaksch, P., Taghavi, S., Muraközy, G., Lang, G., Hager, H., et al. (2017) Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension on Intraoperative and Postoperatively Prolonged Extracorporeal Membrane Oxygenation Provides Optimally Controlled Reperfusion and Excellent Outcome. European Journal of Cardio-Thoracic Surgery, 53, 178-185. [Google Scholar] [CrossRef] [PubMed]
[58] Ojopi, E.P.B., Tonon, C.R., Okoshi, K. and Okoshi, M.P. (2024) Hipertensão Arterial Pulmonar: Intervenções para Cardioproteção. Arquivos Brasileiros de Cardiologia, 121, e20240445. [Google Scholar] [CrossRef] [PubMed]
[59] Madonna, R. and Biondi, F. (2024) Sotatercept: New Drug on the Horizon of Pulmonary Hypertension. Vascular Pharmacology, 157, Article ID: 107442. [Google Scholar] [CrossRef] [PubMed]

为你推荐